Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.
about
Growth hormone and reproduction: a review of endocrine and autocrine/paracrine interactionsTargeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.Antagonistic analogs of growth hormone-releasing hormone increase the efficacy of treatment of triple negative breast cancer in nude mice with doxorubicin; A preclinical studyPotentiating effects of GHRH analogs on the response to chemotherapy.New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor.Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN.Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancerNew therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1-STAT3/NF-κB signalingSFMBT2 (Scm-like with four mbt domains 2) negatively regulates cell migration and invasion in prostate cancer cells.Clinical Effect of Switching from a Luteinizing Hormone-Releasing Hormone Agonist to an Antagonist in Patients with Castration-Resistant Prostate Cancer and Serum Testosterone Level ≥ 20 ng/dl.Growth hormone-releasing hormone antagonist inhibits the invasiveness of human endometrial cancer cells by down-regulating twist and N-cadherin expression.Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cells.Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer.Magnetoelectric nanoparticles for delivery of antitumor peptides into glioblastoma cells by magnetic fields.Inhibitory Effects of Antagonists of Growth Hormone-Releasing Hormone (GHRH) in Thyroid Cancer.Expression of Receptors for Pituitary-Type Growth Hormone-Releasing Hormone (pGHRH-R) in Human Papillary Thyroid Cancer Cells: Effects of GHRH Antagonists on Matrix Metalloproteinase-2.Growth hormone-releasing hormone (GHRH) and its agonists inhibit hepatic and tumoral secretion of IGF-1.
P2860
Q28082801-F3833648-E1B3-4951-9519-6CA4F80D1F0DQ34101055-52348152-6113-4555-8ABB-161679B5E645Q34781112-963D3632-83E0-4A23-A1A5-F1DC77E125C9Q35565027-4C9313E0-3099-446D-B5E7-B66163115BADQ35833122-5A7DA3DF-637C-4EF1-8434-358FE464360EQ36020949-BAC32E93-BE06-4EF0-BAAB-30FFCE09E181Q36189529-B00B1238-7EEB-4C5E-923E-CC14320EC43DQ36216457-B6929AE8-DD0E-4894-A91F-71EFBE132F2FQ36748502-1D2FD651-248B-4697-97D5-0AE3FC61ECC5Q37534187-D526FCBA-276F-45A4-99BE-7D22581FF677Q37565445-F97485F8-439E-4DCB-9DEC-966427B8B78AQ38969625-9E44D98C-B17C-4C92-97E1-0DE055359BC9Q41817287-9AB1933F-DECC-462B-B04A-6BD3B742F5AFQ42321749-181D5751-D302-4FDB-91D8-B45B300BC3DBQ42330184-2DF57676-423D-44AA-A806-F9636758273EQ47652837-98A7631F-18A5-470B-9EC5-014A0D70479DQ47765421-D84381D7-0BF4-4763-BEC6-CD620C6E31A4Q48290454-A67DF774-B01B-4FB4-969A-61BEB2E33F11Q55447994-63760062-843E-4ECD-B054-4DBB05C30B1C
P2860
Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Preclinical efficacy of growth ...... sistant human prostate cancer.
@en
Preclinical efficacy of growth ...... sistant human prostate cancer.
@nl
type
label
Preclinical efficacy of growth ...... sistant human prostate cancer.
@en
Preclinical efficacy of growth ...... sistant human prostate cancer.
@nl
prefLabel
Preclinical efficacy of growth ...... sistant human prostate cancer.
@en
Preclinical efficacy of growth ...... sistant human prostate cancer.
@nl
P2093
P2860
P356
P1476
Preclinical efficacy of growth ...... sistant human prostate cancer.
@en
P2093
Cale D Fahrenholtz
Ferenc G Rick
Kerry L Burnstein
Maria I Garcia
Marta Zarandi
Norman L Block
Ren-Zhi Cai
P2860
P304
P356
10.1073/PNAS.1323102111
P407
P577
2014-01-06T00:00:00Z